Want to see KR:118000 full AI Analyst Report?
Metacare Co., Ltd. (118000) AI Stock Analysis
Metacare Co., Ltd.
(Korea Exchange:118000)
The score is held back primarily by deteriorated profitability (recent net loss, compressed margins) and rising leverage, despite improving revenue growth and a return to positive free cash flow. Technicals are mildly supportive in the short term but remain weak over the long term (well below the 200-day average), while valuation is pressured by negative earnings and no available dividend yield.
Metacare Co., Ltd. (118000) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 17.13B
- Dividend Yield
- ―
- Average Volume (3M)
- 48.80K
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 0.06
- Revenue Growth
- 73.09%
- EPS Growth
- -258.84%
- Country
- KR
- Employees
- 32
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
Metacare Co., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Seoul, South Korea, Wooridul Huebrain Limited was founded in 2009. The company's operations span the medical, life and health, pharmaceutical, and storage industries. Its offerings include a range of medical equipment and devices, he...
Metacare Co., Ltd. Financial Statement Overview
Summary
Revenue is growing strongly (+8.1% TTM) and operating profitability remains positive, with improved operating and free cash flow in TTM. However, net income turned negative (about -3.4% net margin), margins have compressed versus 2024, leverage has been rising, and ROE is negative—indicating weakened earnings quality despite better cash generation.
Income Statement
46NeutralBalance Sheet
62PositiveCash Flow
53Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.95B | 32.82B | 20.21B | 17.26B | 19.10B | 18.61B |
| Gross Profit | 8.39B | 7.46B | 7.67B | 6.53B | 6.52B | 5.10B |
| EBITDA | 4.30B | 4.63B | 6.08B | 3.16B | -27.68B | 16.64B |
| Net Income | -1.97B | 498.24M | 9.28B | -14.54B | -49.55B | 7.74B |
Balance Sheet | ||||||
| Total Assets | 243.95B | 197.96B | 156.70B | 155.30B | 189.86B | 176.30B |
| Cash, Cash Equivalents and Short-Term Investments | 11.07B | 1.69B | 30.12B | 22.40B | 29.74B | 59.24B |
| Total Debt | 73.97B | 59.32B | 35.57B | 3.35B | 35.04B | 29.85B |
| Total Liabilities | 106.27B | 76.98B | 41.02B | 17.60B | 60.28B | 56.90B |
| Stockholders Equity | 125.42B | 119.42B | 115.67B | 105.91B | 99.24B | 119.40B |
Cash Flow | ||||||
| Free Cash Flow | 3.16B | -22.79B | 1.58B | -17.89B | -2.70B | -1.52B |
| Operating Cash Flow | 3.74B | 2.42B | 4.48B | -12.86B | -2.53B | -1.49B |
| Investing Cash Flow | -16.96B | -59.68B | -20.09B | 8.83B | -36.72B | 11.85B |
| Financing Cash Flow | 15.54B | 28.80B | 25.59B | -4.36B | 8.49B | 34.17B |
Metacare Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:118000, the sentiment is Negative. The current price of 997.00 is below the 20-day moving average (MA) of 1214.20, below the 50-day MA of 1268.90, and below the 200-day MA of 1889.63, indicating a bearish trend. The MACD of -11.44 indicates Positive momentum. The RSI at 28.13 is Positive, neither overbought nor oversold. The STOCH value of 26.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:118000.
Metacare Co., Ltd. Peers Comparison
Overall Rating
- KR:11800053Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:118000 | 53Neutral | KRW 21.99B | -8.04 | ― | ― | 73.09% | -258.84% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:118000 | Metacare Co., Ltd. | 997.00 | -2143.00 | -68.25% | |
| KR:131220 | Daihan Scientific Co., Ltd | 3630.00 | -927.19 | -20.35% | |
| KR:188260 | SANIGEN Co., Ltd. | 1962.00 | -338.00 | -14.70% | |
| KR:299660 | Cellid Co., Ltd. | 1882.00 | -1368.00 | -42.09% | |
| KR:335810 | Precision Biosensor, Inc. | 1435.00 | -1465.00 | -50.52% | |
| KR:354200 | NGeneBio Co., Ltd. | 695.00 | -2829.06 | -80.28% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026